UBE2A Antibody

What is UBE2A and why is it important in research?

UBE2A (Ubiquitin-conjugating enzyme E2A) is a member of the ubiquitin proteasome pathway that functions as an E2 conjugating enzyme. It plays a critical role in regulating TP53 protein levels under both normal and stress conditions . UBE2A is particularly significant in research because:

• Mutations in UBE2A cause X-linked intellectual disability (XLID) type Nascimento syndrome

• It serves as a node for directing different pathways of DNA damage repair

• It participates in mechanotransduction and contact inhibition pathways

• It works with its paralog UBE2B to regulate TP53 levels in a "yin-yang" manner

The protein has an observed molecular weight of 17 kDa and is encoded by a gene located on the X chromosome .

What are the optimal applications for UBE2A antibodies in research?

Based on validated research applications, UBE2A antibodies are most effectively used in:

For IHC applications, antigen retrieval with TE buffer pH 9.0 is recommended; alternatively, citrate buffer pH 6.0 may be used . It's important to titrate the antibody in each specific testing system to obtain optimal results.

How is UBE2A protein expressed in normal versus pathological tissues?

UBE2A shows distinctive expression patterns in normal versus diseased tissues:

• In normal tissues: UBE2A is weakly detected in adjacent normal tissue samples and normal human liver HL-7702 cells

• In hepatocellular carcinoma (HCC): UBE2A is significantly overexpressed at both mRNA (9.55±8.84 in HCC vs. 5.74±2.25 in adjacent normal tissue, P<0.01) and protein levels

• Cellular localization: UBE2A is expressed in the nuclei and cytoplasm of HCC cells, but primarily located in the cytoplasm

• Cell line expression: Significantly higher expression is observed in HCC cell lines (HePG2, 1.67±0.02; Huh-7, 2.56±0.15; Bel-7402, 2.34±0.07; SNu-423, 2.30±0.06; Bel-7701, 2.14±0.07) compared to normal liver cells (HL-7702, 0.89±0.12; P<0.001)

This differential expression makes UBE2A antibodies valuable for studying pathological processes in certain cancers.

What are the optimal protocols for UBE2A detection in Western blotting?

For successful Western blot detection of UBE2A:

• Sample preparation and protein extraction:

  • Use RIPA lysis buffer including phosphatase inhibitor cocktail

  • Centrifuge lysates at 10,000 × g for 10 min at 4°C

  • Measure protein concentration using BCA Protein Assay kit

• Electrophoresis and transfer:

  • Separate equal amounts of protein by 10% SDS-PAGE

  • Transfer onto nitrocellulose membranes at 100 V for 90 min

• Antibody incubation:

  • Primary antibody: Use anti-UBE2A (such as RAD6, cat. no. ab31917) at 1:1,000 dilution

  • Incubate overnight at 4°C

  • Secondary antibody: Use HRP-conjugated goat anti-rabbit IgG at 1:3,000 dilution

  • Incubate at room temperature for 1 hour

• Detection:

  • Visualize using an enhanced chemiluminescence system

  • Analyze grey values using Image J software or equivalent

Always include β-actin (or similar housekeeping protein) as a loading control.

What are the recommended procedures for UBE2A immunohistochemistry?

For optimal immunohistochemical detection of UBE2A:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24 hours at room temperature

  • Embed in paraffin and prepare 4-μm sections

• Antigen retrieval and blocking:

  • Deparaffinize sections through xylene baths and graded alcohols

  • Perform antigen retrieval by microwaving slides in citrate buffer (pH 6.0) for 10 minutes , or alternatively use TE buffer (pH 9.0)

  • Block endogenous peroxidase activity with 3% H₂O₂ for 15 minutes at room temperature

• Antibody incubation:

  • Primary antibody: Incubate with anti-UBE2A (such as cat. no. ab31917) at 1:200 dilution overnight at 4°C , though dilutions between 1:50-1:500 may be appropriate depending on specific application

  • Secondary antibody: Apply HRP-conjugated anti-mouse/rabbit secondary antibody for 30 minutes at room temperature

• Visualization and counterstaining:

  • Perform DAB staining for 1 minute at room temperature

  • Counterstain with hematoxylin

  • Score UBE2A expression on a scale of 0–3 based on staining intensity

How can researchers validate the specificity of UBE2A antibodies?

To ensure antibody specificity, researchers should implement multiple validation strategies:

• Genetic validation approaches:

  • Use UBE2A knockout models as negative controls

  • Utilize iPSC-based cell models with knockout and inducible hyperexpression of UBE2A

  • Test antibodies on samples from patients with UBE2A mutations or deletions

• Molecular validation methods:

  • Confirm observed molecular weight matches expected size (17 kDa)

  • Validate reactivity across multiple sample types (cell lines, tissues)

  • Perform peptide competition assays to confirm epitope specificity

• Cross-reactivity assessment:

  • Test against UBE2B (96% amino acid identity with UBE2A)

  • Design experiments to generate antibodies specific to UBE2A and not cross-reactive with UBE2B

• Methodological controls:

  • Include isotype controls to rule out non-specific binding

  • Use multiple antibodies targeting different epitopes of UBE2A

  • Verify subcellular localization patterns match known distribution patterns (nuclei and cytoplasm, primarily cytoplasm)

How can UBE2A antibodies be used to study protein-protein interactions in the ubiquitination pathway?

UBE2A antibodies can be leveraged to investigate complex protein-protein interactions within the ubiquitination cascade through these methodological approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Immunoprecipitate UBE2A using specific antibodies and analyze binding partners

  • Identify interactions with E3 ligases, particularly those containing RING domains

  • Validate UBE2A's interaction with UBR4, an atypical E3 ligase module

  • Study the differential binding preferences between UBE2A and its paralog UBE2B

• Proximity ligation assays (PLA):

  • Visualize and quantify endogenous protein-protein interactions in situ

  • Combine UBE2A antibodies with antibodies against potential interaction partners

  • Map temporal and spatial dynamics of UBE2A-containing complexes

• FRET/BRET assays with antibody validation:

  • Validate protein interactions detected by FRET/BRET using antibody-based methods

  • Confirm the specificity of interactions between UBE2A and E3 ligases

• Structural studies supported by antibody epitope mapping:

  • Use domain-specific UBE2A antibodies to probe functional regions

  • Investigate how mutations affect UBE2A structure and function, particularly in the UBCc domain and C-terminal region

  • Study cryptic zinc finger domains in interaction partners like UBR4

When investigating the UBE2A-UBR4 interaction specifically, researchers should note that UBR4's autoubiquitination activity is robust only when partnered with UBE2A or UBE2B .

What experimental approaches can elucidate UBE2A's role in neurodevelopmental disorders?

To investigate UBE2A's involvement in X-linked intellectual disability and other neurodevelopmental disorders, researchers can employ these methodological strategies:

• iPSC-based disease modeling:

  • Generate iPSCs from patients with UBE2A mutations

  • Create isogenic iPSC lines with CRISPR-Cas9-mediated UBE2A knockout and inducible expression

  • Differentiate iPSCs into neural lineages to study UBE2A's role in neurogenesis

  • Track UBE2A expression during neural differentiation using specific antibodies

• Mutation analysis approaches:

  • Study specific mutations observed in patients (e.g., c.76G>A, p.Gly26Arg)

  • Investigate how C-terminal truncations affect protein function (e.g., Q128X mutation that removes 25 C-terminal amino acids)

  • Examine conserved domains critical for UBE2A function

• Brain-specific expression analysis:

  • Perform immunohistochemistry on brain sections using UBE2A antibodies

  • Compare UBE2A expression patterns in different brain regions

  • Analyze UBE2A levels during brain development

  • Study the consequences of UBE2A mutations on brain structure (e.g., hypoplasia of corpus callosum and basilar part of pons)

• Functional assays:

  • Assess ubiquitination activity using in vitro assays with recombinant UBE2A

  • Compare wild-type vs. mutant UBE2A activity

  • Investigate substrate specificity in neural cells

How can researchers differentiate between UBE2A and UBE2B in experimental systems?

Distinguishing between UBE2A and UBE2B presents a significant challenge due to their 96% amino acid identity and overlapping functions . Researchers can employ these methodological approaches:

• Antibody-based discrimination strategies:

  • Develop antibodies targeting the seven amino acid differences between UBE2A and UBE2B

  • Validate antibody specificity using recombinant proteins and knockout models

  • Employ epitope mapping to identify unique regions for specific antibody development

• Genetic approaches:

  • Use X-chromosome inactivation analysis since UBE2A is X-linked while UBE2B is autosomal

  • Leverage CRISPR-Cas9 to specifically target UBE2A or UBE2B

  • Perform gene-specific knockdown using siRNA targeting unique regions

  • Study UBE2A-specific disease models, as mutations in UBE2A (but not UBE2B) cause X-linked intellectual disability

• Biochemical activity differentiation:

  • Compare intrinsic aminolysis rates (UBE2A discharge rate is at least sixfold higher than UBE2D3)

  • Assess binding preferences to different E3 ligases

  • Study differential responses to structural perturbations (UBE2B appears more sensitive to structural perturbations from A126 mutations)

• Expression pattern analysis:

  • Map tissue-specific expression ratios between UBE2A and UBE2B

  • Investigate cell-type specific differences in expression

  • Examine subcellular localization patterns

What methods can researchers use to study UBE2A structural changes caused by mutations?

To investigate how mutations affect UBE2A structure and function, researchers can implement these approaches:

• Computational simulation approaches:

  • Perform molecular dynamics (MD) simulations to assess structural changes caused by mutations

  • Analyze root-mean-square deviation (RMSD) plots to evaluate global structural impacts

  • Use root-mean-square fluctuation (RMSF) analysis to identify regions with increased flexibility

  • Employ hydrogen bond (hbond) analysis to assess structural stability

  • Utilize Dictionary of Secondary Structure of Proteins (DSSP) plots to evaluate disruption of secondary structures

• Experimental structural biology:

  • Use circular dichroism (CD) spectroscopy to assess secondary structure changes

  • Perform thermal shift assays to evaluate protein stability

  • Employ limited proteolysis to identify structurally altered regions

  • Apply hydrogen-deuterium exchange mass spectrometry to map conformational changes

• Functional correlations with structural alterations:

  • Assess the impact of helix-3 A126 mutations on UBE2A structure and function

  • Investigate how C-terminal truncations (such as the Q128X mutation) affect protein stability

  • Study the functional consequences of mutations in conserved domains, particularly the UBCc domain

• Antibody epitope accessibility:

  • Use domain-specific antibodies to probe structural changes

  • Assess epitope accessibility in native versus denatured conditions

  • Compare wild-type and mutant proteins using conformational antibodies

Research has shown that mutations in helix-3 A126 deform the structures of both UBE2A and UBE2B, with UBE2B appearing more sensitive to structural perturbations .

How can UBE2A antibodies be utilized to study mechanotransduction pathways?

Recent research has identified UBE2A/B as a force- and contact inhibition-dependent nucleocytoplasmic shuttling trans-acting factor (TAF) . Researchers can explore this new role using these methodological approaches:

• Nucleocytoplasmic shuttling analysis:

  • Track UBE2A localization under different mechanical stimuli using immunofluorescence with UBE2A antibodies

  • Compare UBE2A/B translocation with YAP/TAZ movement, as they are distinctively regulated by myosin contraction, actin-polymerization, and contact inhibition (CI)

  • Perform fractionation experiments followed by Western blotting to quantify nuclear versus cytoplasmic UBE2A

• Transcriptional regulation studies:

  • Identify UBE2A-regulated genes through next-generation sequencing

  • Study how UBE2A/B regulates YAP through histone ubiquitination

  • Investigate DNaseI-hypersensitive sites (DHSs) where UBE2A may function as a trans-acting factor

• Force sensing experiments:

  • Apply controlled mechanical forces to cells and monitor UBE2A localization and activity

  • Analyze UBE2A-dependent gene expression changes in response to mechanical stimuli

  • Compare UBE2A/B-mediated pathways with established mechanotransduction pathways

• Cell contact inhibition models:

  • Study UBE2A function in sparse versus confluent cell cultures

  • Investigate how contact inhibition affects UBE2A localization and activity

  • Examine the YAP-independent mechanotransduction pathway mediated by UBE2A/B

This research direction represents an emerging field connecting ubiquitination pathways with cellular mechanical responses.

What are the methodological considerations for studying UBE2A in cancer progression?

UBE2A's overexpression in hepatocellular carcinoma suggests potential roles in cancer progression . Researchers can investigate these roles using:

• Expression correlation analysis:

  • Use UBE2A antibodies for tissue microarray analysis across multiple cancer types

  • Correlate UBE2A expression levels with clinical outcomes

  • Study UBE2A expression in matched tumor/normal pairs

  • Quantify UBE2A levels in different cancer stages to establish prognostic potential

• Functional studies in cancer models:

  • Manipulate UBE2A expression in cancer cell lines through knockdown/overexpression

  • Assess effects on proliferation, migration, invasion, and apoptosis

  • Investigate UBE2A-dependent ubiquitination targets in cancer cells

  • Study effects of UBE2A modulation on drug sensitivity

• Pathway analysis in cancer context:

  • Examine UBE2A's role in DNA damage repair pathways in cancer cells

  • Investigate interactions with known oncogenes and tumor suppressors

  • Study UBE2A's role in regulating TP53 levels in cancer contexts

  • Analyze mechanotransduction pathway alterations in cancer

• In vivo cancer models:

  • Generate xenograft models with modified UBE2A expression

  • Use UBE2A antibodies for tumor immunohistochemistry analysis

  • Track UBE2A expression changes during cancer progression and metastasis

The research showing high UBE2A expression in HCC tissues (strongly positive in 276 HCC tissues versus weak/no expression in 63 adjacent normal tissues, P<0.0001) provides a foundation for further cancer-related investigations.

How can researchers design validation studies for novel UBE2A antibodies?

Developing and validating new UBE2A antibodies requires rigorous methodology:

• Epitope selection strategies:

  • Target unique regions that distinguish UBE2A from UBE2B

  • Design peptides from conserved functional domains for functional studies

  • Consider multiple epitopes to generate antibody panels

• Comprehensive validation workflow:

  • Phase 1: Basic validation

    • ELISA against immunizing peptide/protein

    • Western blot against recombinant protein and endogenous UBE2A

    • Immunoprecipitation efficiency testing

  • Phase 2: Specificity assessment

    • Test on UBE2A knockout/knockdown samples

    • Cross-reactivity testing against UBE2B

    • Peptide competition assays

    • Testing on patient samples with UBE2A mutations

  • Phase 3: Application validation

    • Optimization for specific applications (WB, IHC, IF, ChIP)

    • Determination of optimal working dilutions for each application

    • Reproducibility testing across different sample types

  • Phase 4: Functional validation

    • Testing antibody effects on UBE2A enzymatic activity

    • Epitope accessibility in protein complexes

    • Compatibility with mechanistic studies

• Use of iPSC-based models:

  • Leverage iPSC models with UBE2A knockout and inducible expression

  • Test antibodies on differentiated neural cells from these models

  • Validate antibodies in disease-relevant cellular contexts

Proper validation ensures that antibodies can reliably detect UBE2A across multiple applications and experimental conditions.

What are the common pitfalls in UBE2A detection and how can they be resolved?

Researchers frequently encounter these challenges when working with UBE2A antibodies:

• Cross-reactivity with UBE2B:

  • Problem: UBE2A and UBE2B share 96% amino acid identity , leading to potential cross-reactivity.

  • Solution: Validate antibody specificity using UBE2A knockout samples; perform peptide competition assays; use antibodies raised against unique regions; confirm with alternate detection methods.

• Variable expression levels across tissues:

  • Problem: UBE2A expression ratios vary significantly across tissues , making consistent detection challenging.

  • Solution: Optimize protein loading for each tissue type; use appropriate positive controls; adjust antibody concentration based on expected expression levels; increase sensitivity with enhanced chemiluminescence systems.

• Subcellular localization challenges:

  • Problem: UBE2A is present in both nucleus and cytoplasm but predominantly cytoplasmic , complicating complete protein extraction.

  • Solution: Use extraction methods that efficiently collect both nuclear and cytoplasmic fractions; validate fractionation efficiency; consider cell-type specific differences in localization.

• Low signal-to-noise ratio in IHC:

  • Problem: Background staining can obscure specific UBE2A detection.

  • Solution: Optimize antigen retrieval (try both TE buffer pH 9.0 and citrate buffer pH 6.0) ; increase blocking duration; titrate primary antibody dilution (1:50-1:500) ; use sensitive detection systems; include appropriate controls.

• Post-translational modification interference:

  • Problem: Ubiquitination pathway proteins can themselves be modified, affecting epitope accessibility.

  • Solution: Use multiple antibodies targeting different epitopes; test under denaturing and native conditions; include deubiquitination inhibitors in lysates when appropriate.

How should researchers interpret discrepancies in UBE2A detection between different experimental methods?

When faced with inconsistent UBE2A detection results across methods, consider these analytical approaches:

• Method-specific variables analysis:

  • Compare native versus denatured detection conditions (WB vs. IP vs. IHC)

  • Assess epitope accessibility in different preparation methods

  • Evaluate fixation effects on antibody binding in IHC/IF

  • Consider differential extraction efficiency between methods

• Sample-specific interpretation:

  • Account for tissue-specific expression levels and isoform distribution

  • Consider disease state effects on UBE2A expression and localization

  • Evaluate X-chromosome inactivation effects in female samples

  • Assess potential post-translational modifications affecting detection

• Technical resolution strategies:

  • Validate with multiple antibodies targeting different epitopes

  • Employ genetic validation via knockdown/knockout approaches

  • Confirm with recombinant protein controls

  • Quantify using absolute standards where possible

• Biological variability considerations:

  • UBE2A translocation between nucleus and cytoplasm may affect detection

  • Mechanotransduction or contact inhibition status may alter UBE2A localization

  • Cell cycle stage may influence UBE2A levels and localization

  • Interaction partners may mask antibody epitopes

Understanding the basis for inter-method discrepancies often reveals important biological insights about UBE2A biology and function.